Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;68(11):1953-1960.
doi: 10.1136/gutjnl-2019-318936. Epub 2019 Jul 11.

IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology

Gareth-Rhys Jones  1   2 , Mathew Lyons  2 , Nikolas Plevris  2 , Philip W Jenkinson  2 , Cathy Bisset  2 , Christopher Burgess  3   4 , Shahida Din  2 , James Fulforth  2 , Paul Henderson  3   4 , Gwo-Tzer Ho  1   2 , Kathryn Kirkwood  5 , Colin Noble  2 , Alan G Shand  2 , David C Wilson  3   4 , Ian Dr Arnott  2 , Charlie W Lees  2
Affiliations

IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology

Gareth-Rhys Jones et al. Gut. 2019 Nov.

Abstract

Objective: IBD prevalence is estimated to be rising, but no detailed, recent UK data are available. The last reported prevalence estimate in the UK was 0.40% in 2003. We aimed to establish the current, and project future, prevalence in Lothian, Scotland.

Design: We conducted an all-age multiparameter search strategy using inpatient IBD international classification of disease (ICD-10) coding (K50/51)(1997-2018), IBD pathology coding (1990-2018), primary and secondary care prescribing data (2009-2018) and a paediatric registry, (1997-2018) to identify 'possible' IBD cases up to 31/08/2018. Diagnoses were manually confirmed through electronic health record review as per Lennard-Jones/Porto criteria. Autoregressive integrated moving average (ARIMA) regression was applied to forecast prevalence to 01/08/2028.

Results: In total, 24 601 possible IBD cases were identified of which 10 499 were true positives. The point prevalence for IBD in Lothian on 31/08/2018 was 784/100 000 (UC 432/100 000, Crohn's disease 284/100 000 and IBD unclassified (IBDU) 68/100 000). Capture-recapture methods identified an additional 427 'missed' cases (95% CI 383 to 477) resulting in a 'true' prevalence of 832/100 000 (95% CI 827 to 837).Prevalence increased by 4.3% per year between 2008 and 2018 (95% CI +3.7 to +4.9%, p<0.0001). ARIMA modelling projected a point prevalence on 01/08/2028 of 1.02% (95% CI 0.97% to 1.07%) that will affect an estimated 1.53% (95% CI 1.37% to 1.69%) of those >80 years of age.

Conclusions: We report a rigorously validated IBD cohort with all-age point prevalence on 31/08/2018 of 1 in 125, one of the highest worldwide.

Keywords: Crohn’s disease; epidemiology; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: NP has received consultancy fees from Takeda and speaker fees and travel support from AbbVie, Takeda and Norgine. SD has received travel support from AbbVie, Dr Falk and consultancy fees from Takeda. AGS has received travel support from AbbVie and Ferring. IA has received consultancy fees from Vifor and travel support from Takeda and Dr Falk. CWL has received research support from Gilead, Oshi Health and AbbVie, consultancy fees from AbbVie, Pfizer, Dr Falk, Hospira, MSD, Gilead, Pharmacosmos, Takeda and Vifor, and speaker fees and travel support from AbbVie, Pfizer, Ferring, Hospira and Takeda. GRJ, PWJ, ML, JF and GTH have no personal interests to declare. PH and SD are supported by an NHS Research Scotland Career Researcher Fellowship. DCW has received consultancy fees, speaker fees and/or travel support from Abbvie, Takeda, Roche, Ferring, Predictimmune, Dr Falk and 4D Pharma.

Figures

Figure 1
Figure 1
Information sources used for IBD case identification. The number of unique cases of putative IBD identified from each information stream, and overall, during the described capture period. All gastroenterology secondary care outpatient appointments between 01/08/2017 and 01/08/2018 at the largest Lothian IBD centre (Western General Hospital) were screened in addition to estimate accuracy of our search strategy. All ‘possible’ cases were then submitted to manual review of the electronic medical record.
Figure 2
Figure 2
The point prevalence of IBD in Lothian on 31/08/2018. True and false positive cases were identified from ‘possible’ cases in figure 1 and used to define accuracy rates for each information stream (Table 3). True positives were screened for prevalent (Lothian postcode) and live (linkage to national datasets) cases to report point prevalence on 31/08/2018.
Figure 3
Figure 3
Age group prevalence breakdown by sex and IBD classification. Prevalent IBD cases were subdivided into age groups by IBD diagnosis into all IBD (red) and UC, CD or IBDU (blue). Percentage prevalence is reported for age-appropriate population data derived from National records for Scotland, 2016-based projections for 2018. CD, Crohn’s disease; IBDU, IBD unclassified.
Figure 4
Figure 4
Incidence, mortality and age at diagnosis by IBD subtype changes between 2008 and 2018. Incident cases were identified by using the date of diagnosis obtained during case verification. Mortality data were obtained from national registry linkage. Incidence and prevalent IBD cohort mortality (A), with IBD subtype incidence breakdown (B), age at diagnosis for prevalent cases on 31/08/2018 overall (C) and for IBD subtype (D). CD, Crohn’s disease; IBDU, IBD unclassified.
Figure 5
Figure 5
Projected IBD prevalent cases±95% CI from 2018 to 2028. Retrospective prevalence data were imputed monthly from 01/01/2008 to 31/08/2018 to model age-group projected future prevalence to 31/08/2028 (A), with absolute prevalent case number per age group for actual prevalence on 31/08/2018 and projected prevalence on 01/08/2028 (B). 2016-based population projections were obtained from 2018 to 2028 from National records for Scotland data.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Coward S, Clement F, Benchimol EI, et al. . Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 2019;156:1345–53. 10.1053/j.gastro.2019.01.002 - DOI - PubMed
    1. Ng SC, Shi HY, Hamidi N, et al. . Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769–78. 10.1016/S0140-6736(17)32448-0 - DOI - PubMed
    1. Rubin GP, Hungin AP, Kelly PJ, et al. . Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553–9. 10.1046/j.1365-2036.2000.00886.x - DOI - PubMed
    1. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Eur J Gastroenterol Hepatol 2003;15:1275–80. 10.1097/01.meg.0000085500.01212.e2 - DOI - PubMed
    1. Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016;7:51–65. 10.4292/wjgpt.v7.i1.51 - DOI - PMC - PubMed

Publication types